59 episodes

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Medical Industry Feature ReachMD

    • Science

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

    Measuring Depth of Remission in Chronic Lymphocytic Leukemia

    Measuring Depth of Remission in Chronic Lymphocytic Leukemia

    Guest: Matthew S. Davids, MD, MMSc


    In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts.
    ABBV-US-00196-MC
    Version 1.0, Approved August 2020

    Dietary Management of Blood Glucose in Critically Ill Overweight & Obese Patients

    Dietary Management of Blood Glucose in Critically Ill Overweight & Obese Patients

    Guest: Todd Rice, MD


    Dive into the DIVINE study with Dr. Todd Rice, a pulmonologist and Associate Professor of Medicine at Vanderbilt University Medical Center. Dr. Rice explores the factors that have prompted a reassessment of macronutrient roles in critical illness and the results from the DIVINE study, which investigated whether a very high protein and lower carbohydrate enteral nutrition formula could facilitate improved glucose control while avoiding worsening hyperglycemia.

    Dual Pathway Inhibition: A Different Antithrombotic Strategy for Patients With CAD/PAD

    Dual Pathway Inhibition: A Different Antithrombotic Strategy for Patients With CAD/PAD

    Host: Jennifer Caudle, DO

    Guest: Sandeep Nathan, MD


    Tune in as Dr Sandeep Nathan discusses treatment guidelines for thrombotic risk reduction in patients with chronic CAD/PAD and shares data on these patients from the REACH Registry. Dr Nathan will also explain a different treatment paradigm, dual pathway inhibition, using XARELTO® 2.5 mg twice daily plus low-dose aspirin once daily for the reduction in the risk of major cardiovascular events.
    This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultant is a paid speaker for Janssen Pharmaceuticals, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.
    ©Janssen Pharmaceuticals, Inc. 2020 July 2020 cp-147541v1

    Practical CDE Insights Toward the 2020 ADA Standards of Medical Care in Diabetes for Glycemic Control

    Practical CDE Insights Toward the 2020 ADA Standards of Medical Care in Diabetes for Glycemic Control

    Host: Jennifer Caudle, DO

    Guest: Lisa A. Coco, CRNP

    Guest: Deborah Hinnen, NP

    Guest: Davida F. Kruger, CNP


    When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020

    Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Host: Matt Birnholz, MD

    Guest: Gary Cohen, MD


    What’s the difference between a generic drug and biosimilar? How does the FDA define biosimilarity? And how are biosimilars developed? Get answers to these and other questions with Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC, in the first episode of this two-part video.
    ©2020 Amgen Inc. All rights reserved. USA-CBU-80726 10/20

    Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

    Host: Matt Birnholz, MD

    Guest: Gary Cohen, MD


    Biosimilars undergo a rigorous evaluation process to ensure high quality and no clinically meaningful difference between biosimilars and the reference product. To learn more about how biosimilar clinical trials are designed to confirm biosimilarity, tune in to the second episode of this two-part series featuring Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC.
    ©2020 Amgen Inc. All rights reserved. USA-CBU-80729 10/20

Top Podcasts In Science

Listeners Also Subscribed To

More by ReachMD